Literature DB >> 31082724

Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.

Christopher Khayeka-Wandabwa1, Xiaoshuang Ma1, Xiaolin Cao1, Venkatrao Nunna1, Janak L Pathak1, Rita Bernhardt2, Pengcheng Cai3, Matthias Bureik4.   

Abstract

It is thought that autoantibody (aAb) production can be caused by (aberrant) protein targeting to the plasma surface of cells. We recently demonstrated the presence of the human cytochrome P450 enzyme CYP4Z1 on the plasma membrane of MCF-7 breast cancer cells and the detection of high titers of anti-CYP4Z1 aAbs in breast cancer patients, but not in healthy controls. In the present study we show that cells of the normal breast cell line MCF-10A do not display CYP4Z1 on their surface. By contrast, we detected CYP19A1 (aromatase) on the plasma membrane of both cell lines. Interestingly, the presence of CYPs on the cell surface did not correlate with their relative expression levels in these cell lines. Indirect ELISA experiments demonstrated the presence of anti-CYP19A1 aAbs in female breast cancer patient sera as well as in male and female controls, respectively; aAb titers in all three groups varied considerably and overall, the results obtained for each group were not significantly different from those of either of the other two groups. Based on these data we propose the hypothesis that CYP translocation to the plasma membrane, but not the intracellular expression level, is the crucial precondition for the generation of anti-CYP aAbs.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Aromatase; Autoantibody; Breast cancer; CYP19A1; CYP4Z1

Mesh:

Substances:

Year:  2019        PMID: 31082724     DOI: 10.1016/j.intimp.2019.05.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues.

Authors:  Yousef M Al-Saraireh; Nafea S Alboaisa; Hamzeh Mohammad Alrawashdeh; Omar Hamdan; Sameeh Al-Sarayreh; Jehad M Al-Shuneigat; Mohammad N Nofal
Journal:  Ecancermedicalscience       Date:  2020-09-29

2.  New Proluciferin Substrates for Human CYP4 Family Enzymes.

Authors:  Jingyao Liu; David Machalz; Gerhard Wolber; Erik J Sorensen; Matthias Bureik
Journal:  Appl Biochem Biotechnol       Date:  2020-09-01       Impact factor: 2.926

Review 3.  Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications.

Authors:  Yazun Bashir Jarrar; Su-Jun Lee
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

4.  Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Yahya M Al-Sarayra; Renata A Al-Saraireh; Ghadeer H Al-Muhaisen; Yanal S Al-Mahdy; Ahlam M Al-Kharabsheh; Seham M Abufraijeh; Hamzeh Mohammad Alrawashdeh
Journal:  Curr Oncol       Date:  2021-09-16       Impact factor: 3.677

5.  Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Sameeh Al-Sarayreh; Ghadeer H Almuhaisen; Nedal Alnawaiseh; Jehad M Al-Shuneigat; Hamzeh M Alrawashdeh
Journal:  Onco Targets Ther       Date:  2021-11-12       Impact factor: 4.147

6.  Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Fatima Al-Tarawneh; Sameeh Al-Sarayreh; Ghadeer H Almuhaisen; Anas O Satari; Jehad Al-Shuneigat; Hamzeh Mohammad Alrawashdeh
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-10-05

7.  Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Sameeh Al-Sarayreh; Ghadeer H Almuhaisen; Nedal Alnawaiseh; Jehad M Al Shuneigat; Hamzeh M Alrawashdeh
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.